Novel oral anticoagulants and gastrointestinal bleeding: A case for cardiogastroenterology

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 4, 2013, Pages 324-328

  Abraham, Neena S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; DAREXABAN; EDOXABAN; LIXIANA; PRASUGREL; RIVAROXABAN; TICAGRELOR; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; AGED; CARDIOLOGY; CASE REPORT; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FIBRINOLYTIC THERAPY; GASTROENTEROLOGY; GASTROINTESTINAL HEMORRHAGE; HEART PROTECTION; HUMAN; MALE; META ANALYSIS (TOPIC); NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACUTE CORONARY SYNDROME; AGED; ANTICOAGULANTS; CORONARY THROMBOSIS; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84875366461     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.12.013     Document Type: Note

References (20)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011, 123:e18-e209.
2. Abraham N.S., Hlatky M.A., Antman E.M., et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 2010, 122:2619-2633.
3. Jneid H., Anderson J.L., Wright S., et al. ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012, 60:645-681.
4. Fox K.A., Dabbous O.H., Goldberg R.J., et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006, 333:1091.
5. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361:1045-1057.
6. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001-2015.
7. Komócsi A., Vorobcsuk A., Kehl D., et al. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2012, 24:1-9.
8. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994, 308:81-106.
9. Anand S.S., Yusuf S., Pogue J., et al. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. Circulation 1998, 98:1064-1070.
10. Diener H.C., Bogousslavsky J., Brass L.M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic qjattack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004, 364:331-337.
11. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
12. Pocock S.J., Mehran R., Clayton T.C., et al. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy Trial. Circulation 2010, 121:43-51.
13. Sørensen R., Hansen M.L., Abildstrom S.Z., et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009, 374:1967-1974.
14. Hallas J., Dall M., Andries A., et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population-based case-control study. BMJ 2006, 333:726.
15. Buresly K., Eisenberg M.J., Zhang X., et al. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med 2005, 165:784-789.
16. Abraham N.S., Naik A.D., Richardson P., et al. Complex antithrombotic therapy (CAT) and national risk of upper gastrointestinal bleeding (UGIB), lower gastrointestinal bleeding (LGIB), transfusions and hospitalizations. Gastroenterology 2012, 142:S28.
17. Abraham N.S., Naik A.D., Richardson P., et al. Complex antithrombotic therapy (CAT) and the risk of upper gastrointestinal events (UGIE) among vulnerable elders. Gastroenterology 2009, 136:A29.
18. De Caterina R., Husted S., Wallentin L., et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol 2012, 59:1413-1425.
19. Jackevicius C.A., Li P., Tu J.V. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 2008, 117:1028-1036.
20. Johansson F. The Medici effect: what elephants and epidemics can teach us about innovation 2006, Harvard Business Review Press, Boston.